" class="no-js "lang="en-US"> Chris Torrance - Medtech Alert
Tuesday, May 06, 2025

Breaking News

Eloxx Pharmaceuticals Announces Final Data Assessment from Phase 2 Combination Clinical Trial of ELX-02 in Class 1 Cystic Fibrosis Patients Verge Genomics Announces Positive Safety and Tolerability Data from the Phase 1 Clinical Trial of VRG50635, a Potential Best-in-Class Therapeutic for All Forms of ALS DEM BioPharma Appoints Wendy Young, Ph.D., to Scientific Advisory Board Confo Therapeutics Enters into Research Collaboration for GPCR-Targeting Antibody Discovery with AbCellera Vyriad Announces Expansion of T-Cell Lymphoma Trial at Mayo Clinic Astellas and Cullgen Enter into Strategic Collaboration and Option Agreement to Advance Innovative Targeted Protein Degraders Auxilius Pharma Raises Seed Funding of $1 Million and Commences its Clinical Program Captivate Bio and EverCell Bio partner on Human Cell Modeling Services for Cell and Gene Therapy Markets Applied StemCell Partners with CIRM to Provide Clinical-Grade iPSCs and Access to Its Proprietary Gene Editing Technologies Alentis Therapeutics Receives IND Clearance from FDA for ALE.C04 for the Treatment of CLDN1+ Tumors
Chris Torrance

Chris Torrance

About Chris Torrance

‘PhoreMost Therapeutics’ is a Start-up Biotech company that aims to ‘drug the undruggable’

We are launching a phenotypic screening platform that is able to reveal cryptic druggable sites in specific targets/pathways in a live-cell context and then de-orphan these targets with functional lead-molecules for partnering with Pharma

Related Story

News

 PhoreMost Expands into New Facility at Unity Campus

PhoreMost Expands into New Facility at Unity Campus, Cambridge, UK

January 19 2022

PhoreMost Ltd., the UK-based biopharmaceutical company dedicated to ‘Drugging the Undruggable®’ disease targets, today announced […]

Diseases

 NeoCura and PhoreMost Announce Research Collaboration to Explore Novel Cancer Therapeutics | Pharmtech Focus

NeoCura and PhoreMost Announce Research Collaboration to Explore Novel Cancer Therapeutics

January 12 2022

NeoCura Bio-Medical Technology Co., Ltd. (“NeoCura”), a leading RNA-based drug research and development company in […]

Diseases

 PhoreMost and POLARISqb Announce a Multi-target Collaboration to Investigate Next-generation Cancer Therapies | Pharmtech Focus

PhoreMost and POLARISqb Announce a Multi-target Collaboration to Investigate Next-generation Cancer Therapies

January 5 2022

PhoreMost Limited, a UK-based biopharmaceutical company dedicated to developing drugs against intractable disease targets, and […]